Abstract: SA-PO0456
Estimated Plasma Volume Status (ePVS) as a Predictor of Hemodialysis Arteriovenous Fistula on the Primary Patency After Percutaneous Transluminal Angioplasty
Session Information
- Dialysis: Vascular Access
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 803 Dialysis: Vascular Access
Authors
- Luo, Xuyang, Department of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
- Deng, Fei, Department of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
Background
Percutaneous transluminal angioplasty (PTA) is an important method for evaluating hemodialysis dysfunction. We investigated factors associated with plasma volume status and post-PTA primary patency rate in patients with AVF, including the ePVS and previously reported factors. The increase in plasma volume is one of the main mechanisms leading to the occurrence and deterioration of CKD, and it is also associated with the poor prognosis of AVF patients after PTA.
Methods
The medical records at our hospital were collected to retrospectively identify and analyze general information, clinical characteristics, and hemodialysis-related factors for post-PTA primary patency in a cohort of 104 patients with AVF who underwent PTA after vascular access construction between January 2019 and December 2023. They were followed up for 12 months. When the patients needed to be treated with PTA or AVF reconstruction due to re-occlusion, follow-up was terminated. However, this method is technically difficult, invasive, and unsuitable for frequent clinical use to manage plasma volume. To resolve these problems, Hematocrit and hemoglobin were measured at baseline when the participants provided their blood samples. ePVS was calculated according to the following formulas: D-ePVS = (100 − hematocrit (%))/hemoglobin (g/dl), which was Duarte formula-based ePVS (D-ePVS).
Results
Multivariate analysis with the Cox proportional hazard model showed that post-PTA primary patency in patients with AVF is significantly associated with the ePVS (hazard ratio 2.264, 95% confidence interval 1.291 ~ 3.968, P＝0.004). ROC curve analysis showed that ePVS was statistically significant (AUC=0.637, 95% confidence interval 0.500 - 0.774; P<0.001) and had predictive value. In addition, restricted cubic spline (RCS) was used to analyze the relationship between ePVS and post-PTA primary patency in patients with AVF. Overall, ePVS was found to be latent non-linearly correlated to the post-PTA primary patency in patients with AVF in the study (P for overall = 0.003, P for nonlinear = 0.747). In addition, the association of ePVS and the prevalence of post-PTA primary patency in patients with AVF remained consistent in most subgroups (P for interactions>0.05).
Conclusion
ePVS is an important predictive factor for post-PTA primary patency in patients with AVF.